Papillary renal cell carcinoma

Common Name(s)

Papillary renal cell carcinoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Papillary renal cell carcinoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Papillary renal cell carcinoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Papillary renal cell carcinoma" returned 96 free, full-text research articles on human participants. First 3 results:

[Papillary renal cell carcinoma: clinic and pathological study about 27 cases].
 

Author(s): Mohamed Mourad Gargouri, Walid Bargaoui, Yousri Kallel, Yassine Nouira

Journal: Tunis Med. 2015 Jun;93(6):381-5.

 

Papillary renal cell carcinoma (PRCC) represent 10 to 15% of renal tumours in adults. They contain more than 75% of tubule-papillary structure and are divided histologically into two subtypes. The distinction between these two sub-types is essential because of different prognosis.

Last Updated: 8 Dec 2015

Go To URL
Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.
 

Author(s): Xiaolu Yin, Tianwei Zhang, Xinying Su, Yan Ji, Peng Ye, Haihua Fu, Shuqiong Fan, Yanying Shen, Paul R Gavine, Yi Gu

Journal:

 

To investigate the relationships between Chromosome 7 gain, mesenchymal-epithelial transition factor (MET) gene copy number increase and MET protein overexpression in Chinese patients with papillary renal cell carcinoma (PRCC), immunohistochemistry (IHC), immunofluorescence (IF) and ...

Last Updated: 5 Dec 2015

Go To URL
A Patient With Newly Diagnosed Metastatic Type 2 Papillary Renal Cell Carcinoma.
 

Author(s): María T Bourlon, Monica Meneses-Medina, Sara Vázquez-Manjarrez, Francisco M Bustamante-Romero, Adriana C Gallegos-Garza, Elaine T Lam

Journal: Oncology (Williston Park, N.Y.). 2015 Nov;29(11):880-6.

 

Last Updated: 17 Nov 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Papillary renal cell carcinoma" returned 3 free, full-text review articles on human participants. First 3 results:

Low enhancing papillary renal cell carcinoma diagnosed by using dual energy computerized tomography: a case report and review of literature.
 

Author(s): Shaheen Alanee, Danuta I Dynda, Patrick Hemmer, Bradley Schwartz

Journal:

 

Papillary renal cell carcinoma (pRCC) is a mixed group of tumors that constitutes about 15-20% of all renal cortical cancers. Strong enhancement on computerized tomography (CT) is a feature of clear cell, but not of pRCC making the differentiation of papillary tumors from benign cysts ...

Last Updated: 6 Jan 2015

Go To URL
Sporadic bilateral synchronous multicentric papillary renal cell carcinoma masquerading as bilateral multifocal pyelonephritis.
 

Author(s): V S Karthikeyan, L N Dorairajan, S Kumar, A R Vijayakumar, A Ramesh, N Ganesh Rajesh, D Halanaik, S Gupta

Journal: Ann R Coll Surg Engl. 2014 Jul;96(5):e7-10.

 

Pyelonephritis is defined as an inflammation of the kidney and renal pelvis. The diagnosis is usually clinical. Acute multifocal bacterial nephritis is a rare form of pyelonephritis that is more severe and sepsis is more common. We report a patient who presented with fever and right-sided ...

Last Updated: 4 Jul 2014

Go To URL
Tumor-to-tumor metastasis: Renal cell carcinoma metastatic to papillary carcinoma of thyroid-report of a case and review of the literature.
 

Author(s): Olga L Bohn, Luis E De las Casas, Marino E Leon

Journal: Head Neck Pathol. 2009 Dec;3(4):327-30.

 

Metastatic disease to thyroid gland is a rare event. Although renal cell carcinoma (RCC) has been reported to metastasize the thyroid gland, metastatic RCC to a thyroid neoplasm is very unusual. We report a case of a 68-year-old man with history of RCC who presented with a 2.5-cm ...

Last Updated: 2 Jul 2010

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
 

Status: Recruiting

Condition Summary: Renal Cell Carcinoma; Hereditary Leiomyomatosis and Renal Cell Cancer; Papillary Renal Cell Carcinoma, Sporadic

 

Last Updated: 9 Jun 2016

Go to URL
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
 

Status: Recruiting

Condition Summary: Papillary Renal Cell Carcinoma

 

Last Updated: 1 Apr 2016

Go to URL
Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
 

Status: Recruiting

Condition Summary: Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma

 

Last Updated: 29 Jun 2016

Go to URL